Articles tagged with Positron Emission Tomography
A study by Medical University of Vienna shows that PET/CT scans can detect aggressive forms of head and neck cancer at an early stage due to specific patterns reflecting biological activity. Modern imaging helps identify targeted treatment strategies for a type of cancer difficult to treat.
Recent research published in The Journal of Nuclear Medicine has made significant advancements in brain imaging and cancer treatment. A new wearable brain imaging system, SmartBrain, enables real-time imaging beyond the lab, capturing high-resolution images of brain activity without requiring patients to remain still.
A new pretargeted radioimmunotherapy technique has been shown to be effective and safe in eradicating tumors from a preclinical colorectal cancer model. The multi-step theranostic approach delivers alpha-emitting radiation directly to tumors while limiting exposure to healthy tissues.
Researchers have made significant breakthroughs in prostate cancer treatment with new imaging techniques and targeted therapies, including a PSMA-targeting antibody and a CD44v6-targeting radiotherapy. These advancements aim to improve patient outcomes by tailoring diagnosis and treatment to individual needs.
The SNMMI 2026 Annual Meeting will showcase the latest scientific developments driving advances in nuclear medicine, including earlier diagnosis, personalized treatment, and improved disease management for various conditions. The meeting will feature over 150 scientific sessions, satellite symposia, and a cutting-edge exhibit hall.
A new PET biomarker outperforms established risk scores in predicting survival for large B-cell lymphoma patients. Metabolic tumor volume, derived from PET imaging, was found to be an important predictor of progression-free survival.
Researchers developed a new chelator to improve cancer imaging and therapy. Additionally, analyzing brain glucose uptake in patients with non–small cell lung cancer may help predict prognosis. A targeted PET imaging agent is also being developed to detect liver cancer more effectively.
Researchers have developed new PET tracers that can track synaptic density in epilepsy and monitor tau buildup in Alzheimer's disease. A novel PET tracer also maps cellular energy use across the body, enabling faster imaging approaches for studying mitochondrial function.
Recent studies published in The Journal of Nuclear Medicine have made significant advancements in the field. Researchers have developed a new tracer to detect active collagen turnover following myocardial infarction and evaluated folate-based radioconjugates for ovarian cancer imaging. Additionally, targeted radiotherapy shows promise ...
Bidkar aims to develop a novel CD46-targeted radiotheranostic platform to treat metastatic castration-resistant prostate cancer. His proposal focuses on overcoming tumor heterogeneity and improving treatment outcomes.
Kiran Solingapuram Sai's research aims to detect microtubule dysfunction early in Alzheimer's disease using a first-in-class PET radiotracer. The study will establish a reproducible imaging framework for this target.
The study investigated the link between heart attack-induced inflammation and cognitive decline, as well as the potential of PET-based metabolic tumor volume to predict CAR T-cell therapy outcomes. Additionally, researchers combined advanced imaging with genetic profiling to explore hidden metabolic patterns in recurrent brain cancer.
A new imaging test, PSMA PET/CT scan, has been shown to safely reduce the number of biopsies needed for suspected prostate cancer, with no harm to patients. The PRIMARY2 trial found that the scan could identify low-risk patients who did not need a biopsy, while targeting suspicious areas for those who did.
Researchers at USC identified differences in early Alzheimer's disease-related brain changes across racial and ethnic groups, with Black and Hispanic participants showing higher levels of tau in key memory-related regions. The study highlights the need for more inclusive approaches to studying and diagnosing Alzheimer's disease.
Researchers at Kyoto University developed a PET tracer to quantify beta cell mass in type 1 diabetes patients, revealing lower uptake in those with the disease. This measurement was inversely related to hemoglobin A1c and total daily insulin dose, suggesting its potential as a noninvasive readout of residual beta cell mass.
Researchers have developed new imaging techniques to detect hidden infections, inflammatory diseases, and cancers, while also evaluating the effectiveness of AI-powered tumor measurement and targeted radiotherapy for advanced solid tumors.
A new PET imaging study reveals that ketamine relieves treatment-resistant depression by altering AMPAR in brain regions, providing potential biomarker for personalized treatment. The study found that ketamine increased AMPAR density in several cortical regions and decreased it in reward-related areas, strongly correlating with reducti...
A new targeted PET/CT tracer can detect treatment response in rheumatoid arthritis patients as little as four weeks after treatment initiation. The imaging technique uses macrophages, a type of white blood cell, as a biomarker for disease activity, potentially allowing non-responders to pursue more effective therapies.
Researchers have developed a new PSMA-targeted PET tracer that shows promise in early human studies, providing strong tumor uptake and favorable radiation dosimetry. Additionally, advanced dynamic PET imaging has been used to track heart amyloid buildup more precisely, detecting significant reductions after six months of tafamidis ther...
A novel quantitative imaging approach using PET and MRI can identify limbic-predominant age-related TDP-43 encephalopathy (LATE), a distinct neurodegenerative disorder resembling Alzheimer's disease. This framework may guide targeted diagnostic work-up and personalized care for dementia patients.
Researchers have made significant advancements in nuclear medicine by developing a new reporting framework for PET/CT scans, using targeted radiation therapy to treat sarcoma, and investigating how genetic mutations affect prostate cancer treatment outcomes. These studies aim to improve diagnosis and treatment for various cancers.
Researchers are testing new targeted radiation approaches for early colorectal cancer, HER2-positive breast cancer, and advanced prostate cancer. Imaging tools track treatment movement and help evaluate dosing and safety.
Ken Herrmann will lead the journal for five years, focusing on global engagement and impact. He succeeds Johannes Czernin, who guided JNM through significant growth and expansion.
Researchers used advanced PET imaging techniques to study the effects of traumatic spinal cord injuries on nerve cells. Additionally, whole-body PET scans were used to map brain-body immune cross-talk during immune responses.
A study found that prenatal alcohol exposure changed aspects of the dopamine system in rhesus monkeys, influencing how quickly they drank alcohol in adulthood. The researchers also discovered individualized neuroadaptive responses to drinking, which may promote the transition to alcohol use disorder.
Researchers have developed new CXCR4-targeting radiolabeled peptides for cancer imaging and therapy, producing clear tumor images and extending survival in preclinical testing studies. Additionally, PET scans are being used to predict prostate cancer outcomes, identify primary aldosteronism, and guide treatment decisions.
Researchers developed a novel combined PET imaging approach to personalize radiotherapy for head and neck cancers, creating biologic maps that show tumor characteristics. This strategy led to greater than 90% predicted tumor control probability, outperforming previous literature.
A new AI-driven model predicts patient risk of suffering a major adverse cardiac event (MACE) with higher accuracy than traditional predictive models. This improvement in prognostic risk assessment could help personalize individual care plans and maintain quality of life for patients.
This study introduces a new FAP-targeting peptide that shows strong tumor uptake and effective tumor growth inhibition when paired with lutetium-177. Additionally, researchers have identified distinct metabolic and structural brain patterns that differentiate probable LATE, Alzheimer disease, and their frequent overlap.
Recent studies published in The Journal of Nuclear Medicine explore the use of interim PET scans to predict treatment response and survival in patients with large B-cell lymphoma. Additionally, a phase 2 trial evaluates the safety and effectiveness of a radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) in advanced...
A newly developed radiopharmaceutical pair can precisely detect and effectively treat gastric and pancreatic tumors, completely eradicating tumors in preclinical models. Claudin-18.2-based theranostics could meaningfully change patient care by enabling non-invasive tumor identification and targeted radiation therapy.
Researchers developed new imaging approaches using specialized amino acid PET tracers to visualize aggressive breast, lung, and glioma cancers. The studies showed promising results, highlighting the potential of these tools for future cancer imaging and guiding targeted therapies.
Researchers have developed new PET imaging tracers to detect and treat colorectal, thyroid, and lymphoma cancers. The tracers enable targeted radiation delivery, personalized dosing, and improved detection of inflammation in large blood vessels and liver lesions.
Researchers at Virginia Tech have developed a new method for attaching fluorine-18 to trifluoromethyl groups, enabling the tagging of previously inaccessible targets in PET scans. This breakthrough expands the range of molecules that can be imaged, potentially leading to earlier diagnoses and more targeted treatments for diseases.
Recent studies explored novel biomarkers for kidney cancer spread detection, heart scans for ATTR amyloidosis diagnosis, and radiation therapy delivery for neuroendocrine tumors. Additionally, researchers developed a new PET tracer to track heart-healing cells after a heart attack.
A prospective multicenter trial validated an improved method for predicting treatment benefits in hormone receptor-positive metastatic breast cancer with bone metastases. Metabolic change assessed by FDG-PET/CT accurately predicted progression-free survival as early as 12 weeks after treatment initiation.
Recent studies explore new PET/CT imaging methods for prostate cancer staging and detection. Researchers assess improved performance of these advanced scans in detecting lymph node or bone spread, as well as their impact on treatment plans. Additionally, researchers examine the effectiveness of peptide receptor radionuclide therapy (PR...
A new study published at the Radiological Society of North America annual meeting found that individuals with obesity have a 95% faster increase in Alzheimer's disease biomarkers compared to non-obese individuals. Blood tests were more sensitive than PET scans in capturing the impact of obesity on Alzheimer's pathology.
Several studies examine imaging tools for detecting prostate cancer, testing new PET tracers for spotting aggressive tumors. Researchers also explored a new scan to detect gastrointestinal stromal tumors and improved imaging agents for pancreatic cancer diagnosis.
A new study by UC San Francisco combines genetic risk with cardiovascular disease risk factors to predict who is more likely to develop dementia. The expanded view may help those worried about dementia, as lifestyle changes and improved control of illnesses can reduce brain damage and potentially delay or prevent symptoms.
Researchers have made significant advancements in detecting and treating prostate cancer and ALS using innovative imaging techniques. A new PET tracer has been developed to track Huntington disease protein aggregates, offering a potential noninvasive monitoring tool. Additionally, studies have compared two types of PET scans for spotti...
Researchers developed a detailed kidney model to study radiation distribution, highlighting uneven exposure across different nephron types. Tumor volume changes and PSMA PET imaging also showed promise for predicting outcomes in prostate cancer patients. New targeted therapies and imaging strategies aim to improve diagnosis and treatment.
Researchers have developed a new PET imaging agent that can distinguish true tumor response from inflammation during immune checkpoint inhibitor therapy. This breakthrough has the potential to improve early treatment assessment and patient outcomes.
A new approach to PET imaging can identify patients at risk of poor functional recovery after a heart attack by visualizing CXCR4, a cellular protein involved in inflammation. This technique enables timely implementation of treatments to mitigate inflammation and prevent heart failure progression.
Recent studies published in The Journal of Nuclear Medicine explore the use of artificial intelligence to improve PSMA PET/CT scan interpretation, as well as its impact on treatment decisions for patients with recurrent prostate cancer. Brain metabolic changes and fibroblast activation protein (FAP) PET imaging also reveal new insights...
MetaSeg achieves the same segmentation performance as U-Nets but requires 90% fewer parameters, making medical image segmentation more cost-effective. The new approach leverages implicit neural representations to quickly adjust to new images and decode accurate labels.
Studies have found that men with advanced prostate cancer can benefit from continuing PSMA therapy despite early PSA rise, while a new PET/CT scan may improve surgery decisions in pancreatic cancer. Molecular imaging advancements also hold promise for distinguishing aggressive kidney cancers and guiding treatment decisions.
Recent studies published in The Journal of Nuclear Medicine have made significant breakthroughs in prostate cancer treatment, with multiple therapies showing promise. Researchers have also discovered ways to reduce radiation exposure in PET scans and tracked the effects of alpha therapy on patients.
Researchers have developed promising therapies for advanced prostate cancer, improved brain imaging capabilities, and enhanced liver cancer detection. A new alpha therapy shows promise in treating thyroid cancer, while AI-assisted tracking systems enhance prognosis prediction in prostate cancer imaging.
A $10-million grant from the Weston Family Foundation will fund a project at McGill University to discover new Alzheimer's biomarkers. The ultra-high-sensitivity whole body PET/CT scanner, Panorama GS, will aid in understanding disease progression and developing personalized therapies.
A new PET tracer, 64Cu-NOTA-EV-F(ab′2), has been developed for same-day imaging of triple-negative breast and urothelial bladder cancers. The tracer exhibits rapid tumor accumulation and high specificity in nectin-4 positive tumors, enabling accurate non-invasive visualization of this protein.
Faster PET scans show promise for detecting liver inflammation and metabolic dysfunction-associated steatohepatitis. An AI tool combines multiple PET scans to integrate data from different tracers, improving disease insights. New imaging techniques enhance breast cancer surgery and predict recovery after heart attack.
New PET imaging agents show promise for detecting thyroid and neuroendocrine tumors, as well as reversing fibrosis in the heart. Researchers also explored tau PET scans for Alzheimer's detection and SSTR PET/CT for meningioma diagnosis. These advancements hold potential for improving cancer treatment and patient outcomes.
Researchers developed a new PET tracer that effectively identifies synapse loss in the spinal cord and brain after spinal cord injury. The study found reduced uptake of the tracer at the injury site and in the amygdala and cerebellum, suggesting potential for diagnosing and monitoring spinal cord injuries.
A new study from the University of Turku found that AI systems can accurately evaluate social features from images and videos, comparable to human evaluations. The researchers compared AI's evaluations with those made by over 2,000 humans, showing that AI's results were consistently accurate.
Researchers have developed new PET tracers to monitor immune responses and inflammation beyond the lungs throughout the course of SARS-CoV-2 infection. These breakthroughs offer a new way to visualize changes in lymph nodes, spleen, and bone marrow, supporting faster and more comprehensive imaging.
Researchers are using total-body PET imaging to investigate the relationship between long COVID symptoms and activated immune T cells, as well as blood vessel damage. The goal is to gain a better understanding of how these processes are related and how they contribute to long COVID symptoms.
Researchers have published three studies using new imaging approaches to detect and treat various types of cancer. These advancements include positronium lifetime tomography for sharper scans, targeted radiotherapy for sarcoma patients, and biomarkers for endometrial cancer diagnosis.
Recent studies have shown promising results for triple-targeted cancer therapy, new PET imaging tracers tracking immune activation, and reducing PET scan doses while maintaining diagnostic accuracy. These advancements hold promise for improving cancer treatment outcomes and precision medicine.
A new study from Denmark shows that men with biochemically recurrent prostate cancer who undergo PSMA PET/CT before salvage radiotherapy have improved survival rates compared to those who do not. This research confirms that PSMA PET/CT is a valuable tool for identifying patients likely to benefit from salvage radiotherapy, potentially ...